Information Journal Paper
APA:
Copy. (2017). GCT1021-01, a firstinhuman, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors (NCT02988817). JOURNAL OF CLINICAL ONCOLOGY, 35(-), 0-0. SID. https://sid.ir/paper/746571/en
Vancouver:
Copy. GCT1021-01, a firstinhuman, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors (NCT02988817). JOURNAL OF CLINICAL ONCOLOGY[Internet]. 2017;35(-):0-0. Available from: https://sid.ir/paper/746571/en
IEEE:
Copy, “GCT1021-01, a firstinhuman, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors (NCT02988817),” JOURNAL OF CLINICAL ONCOLOGY, vol. 35, no. -, pp. 0–0, 2017, [Online]. Available: https://sid.ir/paper/746571/en